Central Plains Eye MDs
Center for Glaucoma, Retina & Diabetic Eye Care
Call Today (316) 712-4970
Patient Portal

Closed / Completed Clinical Trial

Text Size A A A

Clinical trials provide many benefits. Great attention is directed to those enrolled in a trial, and participation typically incorporates a significant safety net for rescue therapy should a protocol not prove effective clinically. The number of people that may benefit from information learned through clinical trials is untold. Medicine would be hopelessly behind were it not for these physician and patient supported studies.

Thank you to those who participated in the following trials:

Diabetic Retinopathy

Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy.

Sponsor: Aerpio Therapeutics
ClinicalTrials.gov Identifier: NCT03197870

Enrollment status: CLOSED

Age-Related Macular Degeneration

A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 Versus Aflibercept in Subjects With Neovascular Age-Related Macular Degeneration.

Sponsor: Alcon Research
ClinicalTrials.gov Identifier: NCT02307682

Enrollment status: CLOSED

Diabetic Macular Edema

A 6 month, Phase 2 Randomized, Controlled, Double-masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of Luminate (ALG-1001) as Compared to Avastin in the Treatment of Diabetic Macular Edema (DME).

Sponsor: Allegro Ophthalmic
ClinicalTrials.gov Identifier: NCT01482871

Enrollment status: CLOSED

Posterior Vitreous Detachment

A 6 month, Phase 2 Randomized, Double-masked, Placebo-controlled Multicenter Clinical Trial Designed to Evaluate the Safety and Efficacy of Luminate in inducing PVD in Subjects with Non-Proliferative Diabetic Retinopathy.

Sponsor: Allegro Ophthalmic
ClinicalTrials.gov Identifier: NCT02435862

Enrollment status: CLOSED

PRESERVE - Pegaptanib (Macugen) in diabetic macular edema (DME)

Diabetic Macular Edema (DME) occurs when normal retinal blood vessels become damaged and leak both fluid and protein. This leakage distorts normal retinal architecture and leads to decreased visual acuity.Previous studies have shown that a peptide called VEGF165 is predominant in patients with DME. High levels of VEGF165 may cause the development and progression of diabetic macular edema and retinopathy. The purpose of this study was to evaluate the optimal dosing frequency of Macugen in eyes with Diabetic Macular Edema. This study involved men and women age 18 and older.

Participation in this study lasted approximately 24 weeks.

Enrollment status: CLOSED

Dr. Joe Beck is a caring soul. He and his staff listen to my concerns and patiently answer my many questions. I know I'm getting the most up-to-date and technologically advanced care. I trust Dr. Beck with my eyes. - William R., Judge